Battered Pharma Company Vivus Inc. Plunges on Unexpected CEO Resignation

Jacob Harper  |

A scant six weeks after a proxy fight with the company’s largest stockholder resulted in a a complete overturning of Vivus Inc.'s (VVUS) board and led to the installation of Tony Zook as the new CEO, on Sept 3 Zook abruptly resigned, citing health reasons.

The Mountain, Ca.-based pharma company has had a tumultuous summer. On June 20 the American Medical Association classified obesity as a disease, a decision which opened up the possibility for the company’s anti-obesity drug Qsymia to be covered under patients' insurance plans. Qsymia has previously disappointed in sales, due largely to the drug’s myriad harsh side effects, which were far more severe than rival Arena Pharamceutical’s (ARNA) anti-obesity drug Belviq.

Qsymia has long been touted as a blockbuster, and along with Belviq and Eisia, it is one of only three FDA-approved anti-obesity drugs on the market. Prior to launch, Reuters pegged Qsymia to tally $1.3 billion a year in sales by 2017. However, Qsymia has had an incredibly disappointing start, logging only $4.1 million in sales in the second quarter of 2013, signaling actual demand for the drug is a fraction of what was expected.

Though the AMA decision gave hope for more robust Qsymia sales going forward, it wasn’t enough to stave off a shareholder revolt over the perceived failure of the drug. The proxy fight in July, spurred on by disgruntled shareholders, ousted former CEO and installed Zook, whose success at Astrazenca plc ($AZN) have investors confidence that Qsymia could finally see through its multi-billion dollar potential.

But on Sept. 3 Zook unexpectedly resigned effective immediately, leaving the fate of the company once again uncertain. The board acted quickly to diffuse another proxy fight, and installed former Johnson and Johnson (JNJ) executive Seth Fischer as CEO.

While investors initially seemed to support the move, on the day following the installation of Fischer, Vivus’ shares tanked. The stock tumbled 7.75 percent on Sept 4, ending the day at $11.90 a share.

Though Vivus is only down 3.87 percent on the year, the company has lost a whopping 41.26 percent of its value since Sept. 2012. The stock reached a high of around $29 a share following Qsymia's FDA approval in July 2012.

 

(image of lab courtesy of WIkimedia Commons)

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Companies

Symbol Name Price Change % Volume
JNJ Johnson & Johnson 145.26 -0.17 -0.12 6,848,201 Trade
ARNA Arena Pharmaceuticals Inc. 41.01 0.46 1.13 455,677 Trade
VVUS VIVUS Inc. 2.93 -0.06 -2.01 124,842 Trade
AZN Astrazeneca PLC 38.41 0.23 0.60 6,815,830 Trade
CWLXF Curlew Lake Resources Inc. n/a n/a n/a 0

Comments

Can the Media Solve the Partisan Conflict?

Andrew McCarthy, Contributing Editor, The National Review; Michael Zeldin, CNN Legal Analyst; Celeste Katz, Senior Political Reporter, Glamour; Silvia Davi, SVP, Contributing Editor, Equities.com; and Doug Simon, CEO, D S Simon Media discuss how the media’s role has shaped the landscape for communicators and what the media is trying to do to reduce discord in society.

Emerging Growth

IMV Inc.

Immunovaccine Inc is clinical stage biopharmaceutical company. The Company develops products based on its proprietary vaccine enhancement platform in T cell activating therapies for cancer.